TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has ...

Net Loss: The net loss attributable to Serina common stockholders for the year ended December 31, 2025 was $19.4 million, or $ (1.91) per basic and diluted share, compared to net loss of $11.1 million ...

An outline of estate planning strategies and considerations for asset protection, including using state homestead exemptions, holding property in a tenancy by the entirety (TBE), investing in ...

According to the BIK report for 2025, only 17% of micro‑firms used a bank loan. This does not mean that entrepreneurs do not ...

The "Friendship Tax": How to use simple Promissory Notes to keep loans from killing relationships.

Million in Gross Claims with Expanding Settlement Activity Across Multiple Insurance CarriersActive Negotiations Support Estimated $50–$60 ...

Families with significant estate tax exposure may consider intergenerational split-dollar (IGSD) arrangements, where the ...

Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment ...

An Offer in Compromise allows some taxpayers to settle IRS tax debt for less than they owe. Learn how it works, who qualifies ...

Completed acquisition of the DNA X cryptocurrency trading platformClosed sale of the Company's mobile device assets to NEXA in January 2026Focused on enhancing the DNA X trading platform to prepare ...